Recent advances in dermatology

Clinics in Podiatric Medicine and Surgery

Volumn 19, Issue 1, 2002, Pages 65-78

  Wu, Sandra Jones ^a   Tanphaichitr, Artthapol ^a   Ly, Micki ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BECAPLERMIN; BIOBRANE; BIOMATERIAL; CICLOPIROX; CICLOPIROXOLAMINE; FLUCONAZOLE; GROWTH FACTOR; IMIQUIMOD; IMMUNOMODULATING AGENT; ITRACONAZOLE; PIMECROLIMUS; TACROLIMUS; TERBINAFINE;

CONTROLLED STUDY; DERMATOLOGY; DIABETIC FOOT; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; IMMUNOMODULATION; OINTMENT; ONYCHOMYCOSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN CANCER; SKIN GRAFT; SKIN INFLAMMATION; VIRAL SKIN DISEASE; WOUND CARE; WOUND HEALING;

EID: 0036143294     PISSN: 08918422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-8422(03)00081-8     Document Type: Review

References (33)

1. Topical and intralesional antiviral agents
2. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis
3. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream
4. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis
5. The nails and fungus infections
6. Imiquimod: An immune response modifier
7. The role of growth factors in wound management of diabetic foot ulcers
8. Itraconazole therapy for pedal onychomycosis caused by some non-dermatophyte molds and in mixed infections with dermatophytes and molds: A multicenter study with 36 patients
9. Imiquimod in clinical practice
10. The use of skin substitutes in dermatology
11. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States
12. Ciclopirox nail lacquer solution 8% in the 21st century
13. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis
14. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy
15. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children
16. Cellular and immunologic mechanisms in atopic dermatitis
17. Topical immunotherapy
18. Topical immunomodulators: Introducing old friends and a new ally, tacrolimus
19. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi
20. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients
21. Antiinflammatory activity of antifungal preparations
22. Immunomodulatory and pharmacologic properties of imiquimod
23. Immunohistologic characterization of graftskin (Apligraf)
24. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, safety
25. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers
26. Onychomycosis caused by nondermatophytic molds: Clinical features and response to treatment of 59 cases
27. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: A prospective randomized multicenter clinical trial
28. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: A phase III, randomized, placebo-controlled, double-blind study